Tags

Type your tag names separated by a space and hit enter

Pharmacologic characterization of the antiallergic activity of SK&F 78729-A.
J Pharmacol Exp Ther. 1978 Dec; 207(3):756-66.JP

Abstract

SK&F 78729-A, one of a series of pyranenamine compounds, was studied in several laboratory models of immediate-type hypersensitivity reactions. In vivo, SK&F 78729-A, i.v./p.o., inhibited the antigen-induced rat 48-hr passive cutaneous anaphylaxis by a mechanism other than end-organ antagonism to either histamine or serotonin. In vitro, the compound produced a concentration-related inhibition of the immunologic release of histamine and slow-reacting substance of anaphylaxis from passively sensitized fragmented rhesus monkey and canine lung, and modest inhibition of histamine release from passively sensitized fragmented rhesus monkey skin. Similarly, SK&F 78729-A inhibited the antigen-induced release of histamine from passively sensitized fragmented rat lung. Under certain conditions, SK&F 78729-A inhibited antigen-induced pathophysiologic pulmonary responses in in vivo canine and rhesus monkey models of allergic asthma. The results of these studies suggest that clinically, SK&F 78729-A should exhibit a pharmacologic profile consistent with that of a prophylactic antiallergic agent.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

83359

Citation

Chakrin, L W., and R D. Krell. "Pharmacologic Characterization of the Antiallergic Activity of SK&F 78729-A." The Journal of Pharmacology and Experimental Therapeutics, vol. 207, no. 3, 1978, pp. 756-66.
Chakrin LW, Krell RD. Pharmacologic characterization of the antiallergic activity of SK&F 78729-A. J Pharmacol Exp Ther. 1978;207(3):756-66.
Chakrin, L. W., & Krell, R. D. (1978). Pharmacologic characterization of the antiallergic activity of SK&F 78729-A. The Journal of Pharmacology and Experimental Therapeutics, 207(3), 756-66.
Chakrin LW, Krell RD. Pharmacologic Characterization of the Antiallergic Activity of SK&F 78729-A. J Pharmacol Exp Ther. 1978;207(3):756-66. PubMed PMID: 83359.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacologic characterization of the antiallergic activity of SK&F 78729-A. AU - Chakrin,L W, AU - Krell,R D, PY - 1978/12/1/pubmed PY - 1978/12/1/medline PY - 1978/12/1/entrez SP - 756 EP - 66 JF - The Journal of pharmacology and experimental therapeutics JO - J Pharmacol Exp Ther VL - 207 IS - 3 N2 - SK&F 78729-A, one of a series of pyranenamine compounds, was studied in several laboratory models of immediate-type hypersensitivity reactions. In vivo, SK&F 78729-A, i.v./p.o., inhibited the antigen-induced rat 48-hr passive cutaneous anaphylaxis by a mechanism other than end-organ antagonism to either histamine or serotonin. In vitro, the compound produced a concentration-related inhibition of the immunologic release of histamine and slow-reacting substance of anaphylaxis from passively sensitized fragmented rhesus monkey and canine lung, and modest inhibition of histamine release from passively sensitized fragmented rhesus monkey skin. Similarly, SK&F 78729-A inhibited the antigen-induced release of histamine from passively sensitized fragmented rat lung. Under certain conditions, SK&F 78729-A inhibited antigen-induced pathophysiologic pulmonary responses in in vivo canine and rhesus monkey models of allergic asthma. The results of these studies suggest that clinically, SK&F 78729-A should exhibit a pharmacologic profile consistent with that of a prophylactic antiallergic agent. SN - 0022-3565 UR - https://www.unboundmedicine.com/medline/citation/83359/Pharmacologic_characterization_of_the_antiallergic_activity_of_SK&F_78729_A_ L2 - https://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=83359 DB - PRIME DP - Unbound Medicine ER -